Holen Sie sich die Stockscreener-App
2.07
1.47%
0.03
Handel nachbörslich:
2.07
Schlusskurs vom Vortag:
$2.04
Offen:
$2.04
24-Stunden-Volumen:
129.57K
Relative Volume:
0.51
Marktkapitalisierung:
$40.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.26M
KGV:
-1.0147
EPS:
-2.04
Netto-Cashflow:
$-24.69M
1W Leistung:
-7.17%
1M Leistung:
-10.39%
6M Leistung:
+38.00%
1J Leistung:
-74.32%
1-Tages-Spanne:
$2.01
$2.07
1-Wochen-Bereich:
$1.8782
$2.2752
52-Wochen-Spanne:
$1.11
$10.54
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Vergleichen Sie ANVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.07 | 39.75M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
How high can Annovis Bio Inc. stock goTrend Reversal & Daily Momentum Trading Reports - newser.com
Why analysts raise outlook for Annovis Bio Inc. stock2025 Price Targets & Free Verified High Yield Trade Plans - newser.com
Why Annovis Bio Inc. stock is considered a top pick2025 Investor Takeaways & Community Consensus Trade Signals - newser.com
Canaccord Genuity Maintains Annovis Bio (ANVS) Buy Recommendation - Nasdaq
Canaccord Genuity reaffirms Buy rating on Annovis Bio stock By Investing.com - Investing.com Australia
Canaccord Genuity reaffirms Buy rating on Annovis Bio stock - Investing.com India
Annovis Bio completes $21 million stock and warrant offering - MSN
Is Annovis Bio Inc. stock in buy zone after pullbackJuly 2025 Weekly Recap & Low Risk Investment Opportunities - newser.com
Can IKIO Lighting Limited Achieve Earnings Growth in a SlowdownMarket Liquidity Analysis & AI-Based Predictions Available Free - earlytimes.in
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug - MSN
Does Annovis Bio Inc. show high probability of rebound2025 Price Momentum & Breakout Confirmation Alerts - newser.com
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap - MSN
Why Annovis Bio Inc. stock stays on buy listsWeekly Volume Report & Entry and Exit Point Strategies - newser.com
Annovis Bio Appoints Mark Guerin as CFO to Guide Late-Stage Neurodegenerative Drug Development - citybuzz -
Down Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma - Barchart.com
Annovis Bio names Mark Guerin as new chief financial officer By Investing.com - Investing.com Australia
Annovis Bio names Mark Guerin as new chief financial officer - Investing.com India
Annovis Bio Appoints Mark Guerin as Chief Financial Officer to Support Late-Stage Development of Buntanetap - Quiver Quantitative
Annovis Appoints Mark Guerin as Chief Financial Officer - The Manila Times
Neurodegenerative Drug Developer Annovis Bio Strengthens Leadership with Veteran Biotech CFO Appointment - Stock Titan
Pattern recognition hints at Annovis Bio Inc. upside2025 Analyst Calls & AI Driven Price Predictions - newser.com
Earnings Beat: Is CARS a top pick in the sectorQuarterly Market Review & Daily Growth Stock Tips - khodrobank.com
Bear Alert: Will Annovis Bio Inc. benefit from government policyGap Down & Smart Investment Allocation Insights - خودرو بانک
Annovis Bio Publishes Data on New Crystal Form of Alzheimer’s Drug Candidate - MyChesCo
Annovis Bio up 5% as FDA clears phase 3 buntanetap program for Alzheimer's - MSN
Volatility Watch: What is the implied volatility of Annovis Bio IncJuly 2025 Levels & Consistent Growth Stock Picks - خودرو بانک
Aug Volume: Can Brookfield Business Corporation beat the S&P 500Earnings Miss & Risk Managed Investment Strategies - khodrobank.com
Using data filters to optimize entry into Annovis Bio Inc.2025 Valuation Update & Precise Buy Zone Tips - newser.com
Block Trades: Should you avoid Annovis Bio Inc. stock right nowJuly 2025 Retail & Weekly High Return Forecasts - خودرو بانک
Aug Spikes: Will Annovis Bio Inc stock recover after earningsDividend Hike & Low Drawdown Trading Techniques - خودرو بانک
Analyzing recovery setups for Annovis Bio Inc. investorsOptions Play & Risk Controlled Stock Pick Alerts - newser.com
Growth Recap: Will Annovis Bio Inc outperform the market in YEARWeekly Trade Analysis & Smart Investment Allocation Insights - خودرو بانک
Will breakout in Annovis Bio Inc. lead to full recoveryWeekly Risk Summary & Community Verified Trade Signals - newser.com
Aug Momentum: Will Annovis Bio Inc benefit from government policyMarket Growth Summary & Safe Capital Growth Plans - khodrobank.com
Annovis Bio Inc. stock trend outlook and recovery pathWeekly Investment Report & Fast Entry Momentum Alerts - newser.com
Risks Report: What is HOLOWs 5 year growth outlook2025 Pullback Review & Reliable Momentum Entry Alerts - خودرو بانک
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN
Applying Elliott Wave Theory to Annovis Bio Inc.2025 Risk Factors & Fast Gain Stock Tips - newser.com
Is it time to cut losses on Annovis Bio Inc.July 2025 Setups & High Accuracy Investment Signals - newser.com
Can trapped investors hope for a rebound in Annovis Bio Inc.2025 Market Sentiment & Free Technical Confirmation Trade Alerts - newser.com
Is Annovis Bio Inc. showing signs of accumulation2025 Market Outlook & Expert Curated Trade Setups - newser.com
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap - markets.businessinsider.com
Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference - MSN
Aug Macro: Can Annovis Bio Inc disrupt its industryMarket Movers & Weekly High Return Forecasts - خودرو بانک
US Market Wrap: Is Annovis Bio Inc a defensive stockJuly 2025 Decliners & AI Driven Price Forecasts - خودرو بانک
Nasdaq Moves: Is BLCO affected by consumer sentimentJuly 2025 Recap & Stepwise Trade Signal Implementation - khodrobank.com
Annovis Bio, Inc. Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap - MarketScreener
Annovis Bio Publishes Findings on New Crystal Form of Buntanetap in Peer-Reviewed Journal, Supporting Phase 3 Trial in Alzheimer’s Disease - Quiver Quantitative
New Crystal Form of Alzheimer's Drug Buntanetap Extends Patent Protection to 2040s, Matches Original - Stock Titan
Aug Highlights: Is Annovis Bio Inc. impacted by rising rates2025 Stock Rankings & Free Technical Confirmation Trade Alerts - خودرو بانک
Take Profit: What is the target price for Madrigal Pharmaceuticals Inc. stockJuly 2025 PostEarnings & AI Enhanced Trading Alerts - خودرو بانک
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):